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2012.12.0Abstract Purpose: To assess adherence of non-pharmaceutically sponsored trials (non-PSTs) to
ICH protocol structure guidelines and to estimate the effect of implementing Institutional Review
Board’s (IRB) review on this adherence.
Methods: This is a retrospective exploratory study where 60 non-PST clinical trial protocols
(CTPs) were reviewed and halved to IRB-reviewed CTPs (IRCTPs) and non-IRB-reviewed CTPs
(non-IRCTPs). Adherence score (AS) was calculated as the number of fulﬁlled items or sub-items
divided by their total number.
Results: Three adherence patterns were encountered: (1) items consistently present in both groups
e.g. general and background information, objectives, inclusion criteria and intervention details, (2)
items consistently absent in both groups and included contact information of investigators and trial
sites, product accountability, randomization codes’ management, interim analyses and many other
statistical aspects, and (3) items variably present in both groups where the effect of IRB was veri-
ﬁable. Trial site details, potential beneﬁts, discontinuation and exclusion criteria, and follow up for
adverse events were more encountered in IRCTPs than non-IRCTPs. Withdrawal criteria andOncology, National Cancer
halig, Cairo 11796, Egypt.
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72 A.A. Zeeneldinmonitoring of treatment compliance showed a reverse pattern (p< 0.05 for all). The total AS,
administrative AS and ethics AS for IRCTPs was 43%, 22% and 70% compared to 38%, 16%
and 33% for non-IRCTPs (p< 0.003, <0.001, 0.004), respectively. The scientiﬁc AS was 54%
for both groups (p= 0.87).
Conclusions: IRB-implementation at NCI-Egypt improved ethical and administrative sections of
academic protocols. However, this improvement is modest and needs further actions including
adoption of protocol templates. Scientiﬁc sections were as good after IRB-implementation as they
were before that.
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To protect rights, safety, dignity and well-being of research
participants, a trial should only start after its detailed protocol
is reviewed by an independent ethics committee (IEC) [1]. The
clinical trial protocol (CTP) is an essential component of any
study that serves both as an operation manual and as an
explanatory document. It should specify which patients are eli-
gible, which treatments are to be evaluated, and how each pa-
tient’s response is to be assessed. CTP is not aimed to be a rigid
straight jacket preventing interesting or unexpected ﬁndings,
but rather a well-organized piece of thought regarding a spe-
ciﬁc hypothesis [2].
As suggested by the International Conference on Harmo-
nization document ‘‘Guidelines for Good Clinical Practice,
ICH E6(R1)’’, a list of 16 items that should be included in
any CTP that impacts safety and well-being of human sub-
jects and intends to be submitted to regulatory authorities
in the European Union, Japan, and the United States [3].
Failure to comply with GCP guidelines can lead to exclusion
of questionable data, restriction/exclusion of violators and
notiﬁcation of those affected by the violators to take the
appropriate actions [4]. This drives pharmaceutical companies
to allocate sufﬁcient resources, manpower and expertise
that can effectively manage trails either directly or via
outsourcing.
Non-pharmaceutically sponsored trials (NPSTs), unless
adequately funded and sufﬁciently staffed by experienced
personnel such as the setting of cooperative groups, can
face great difﬁculties to comply with applicable regulations
and guidelines. Academic institutions that treat patients,
educate students and do research struggle to comply with
research-governing regulations and guidelines because their
resources and manpower are spanned over these three
domains.
It is not known whether oncology CTPs in academia out-
side ICH jurisdictions adhere to ICH protocol guidelines. In
addition, it is not clear if adherence to ICH guidelines is af-
fected by whether the protocol is reviewed by an Indepen-
dent/Intuitional Review Board (IRB) or not.
Aims of the study
To assess whether CTPs of NPSTs at the Egyptian National
Cancer Institute (NCI-Egypt) adhere to the uniﬁed standard
protocol format suggested by ICH and to assess whether
adherence is affected by the protocol being reviewed by the lo-
cal IRB or not.Methods
Design and setting
This is an exploratory retrospective study of the before-and-
after design. It was conducted at the Egyptian National Cancer
Institute (NCI-Egypt), Cairo University (CU). NCI-Egypt is
the largest center in the Middle East devoted to cancer treat-
ment, education, and research [5].
CTP identiﬁcation
At NCI-Egypt, there are no databases for study protocols.
However, an ofﬁcial copy of academic protocols is usually kept
in the student’s ﬁle in the Higher Education Affairs. Access to
these protocols is very limited. We got the Higher Administra-
tion approval to access these protocols for the purpose of re-
search. As we are assessing CTPs, we limited our criteria to
the clinical departments.
Inclusion criteria
CTPs were included if they referred to NPSTs and started ac-
crual after the release of ICH E6(R1) guidelines that contain
the section on protocol structure in 1996 [3]. IRB review of
NPST protocols was mandated by NCI-Egypt in the year
2008. We included the immediate 30 CTPs prior the mandate
of IRB review and the immediate 30 CTPs following that man-
date (i.e. a total of 60 CTPs).
Data collection and calculation of adherence scores (AS)
The ICH GCP protocol structure guidelines were mentioned
explicitly in section number 6. It contains 16 items and each
is further divided into several sub-items [3]. These were trans-
formed into a paper CRF (Appendix 1). Each sub-item was
scored (1) if fulﬁlled, (0) if missing or (NA) if non-applicable
and in the latter case it was not scored and was excluded from
calculations. The adherence score of every major item (item
AS) is the sum of the scores of individual sub-items divided
by the total number of sub-items · 100. The total adherence
score of a protocol (protocol AS) is the sum of individual
items’ score divided by the total number of items (i.e.
16) · 100. The 16 items were categorized into 3 groups: scien-
tiﬁc, ethical and administrative. The ﬁrst includes ICH items
6.2–6.6, the second includes item 6.12 only and the third in-
cludes the rest of items [6]. The scientiﬁc, ethical and adminis-
trative score is the sum of items in the group divided by their
Adherence of academic oncology trial protocols to ICH guidelines 73total number · 100. Thus; individual item, scientiﬁc, ethical,
administrative and protocol scores range between 0 and 100.
Statistical analysis
Most sub-items were categorical variables. Adherence scores
were continuous variables. CTPs were divided into two groups;
IRB-reviewed CTPS (IRCTPs) and non-IRB-reviewed CTPs
(non-IRCTPs). Categorical variables were presented as per-
centages and Chi squared test used to assess the difference be-
tween different groups. Numerical variables were presented as
means and standard deviations (SD) or Medians and inter-
quartile ranges (IQRs) and group differences as t-tests. A
probability (p value) < 0.05 was considered statistically
signiﬁcant.
Paper CRFs were transcribed to SPSS software program,
version 15 (Chicago, USA). All analyses were done using the
appropriate statistical function in the program.
Results
The characteristics of the 60 CTPs included in the current
study are shown in Table 1. Assessment of compliance of aca-
demic oncology CTPs to ICH protocol items (Appendix 1)
showed three patterns: always-fulﬁlled, always-missing andTable 1 Characteristics of the 60 protocols reviewed.
Item Number (%)
Intervention
Therapeutic trial 48 (80)
Diagnostic or prognostic trial 12 (20)
Year
2005 11 (18)
2006 10 (17)
2007 9 (15)
2008 15 (25)
2009 8 (13)
2010 7 (12)
Department
Medical oncology 19 (32)
Surgical oncology 17 (28)
Anesthesiology 11 (18)
Pediatric oncology 8 (13)
Radiation oncology 5 (8)
Primary cancer research topic
Breast 14 (23)
Leukemia and lymphoma 10 (17)
Gastrointestinal 6 (10)
Genitourinary 6 (10)
Head and neck 3 (5)
Liver 2 (3)
Lung 2 (3)
Metastatic site of many primaries 4 (7)
Multiple primary sites 7 (12)
Cancer symptoms (e.g. pain) 14 (23)
Study design
A. Phase
II 32 (53)
III 10 (17)
Unspeciﬁed 18 (20)
B. Randomization 19 (32)
C. Blinding 4 (7)variable. The always-fulﬁlled items included most of the gen-
eral and background information, objectives and purpose,
inclusion criteria and details of the intervention (Table 2).
The always-missing items included the contact information
of individuals and sites included in the trials, the trial stopping
rules, product accountability, randomization code manage-
ment, source data to be directly recorded in the CRFs, interim
analyses, statistical criteria for trial termination, managing
missing data and protocol deviations, record keeping, ﬁnance
and insurance, and publication policy (Table 3). The third pat-
tern was the items that varied from one protocol to another.
These include the rest of items. Fulﬁllment of items in this cat-
egory ranged from 3% to 97% (Table 4). For the whole 60
CTPs the mean adherence scores of the 16-items ranged be-
tween 0% and 100% (Table 5). The mean total, administrative,
ethical and scientiﬁc scores were 41%, 19%, 52% and 54%,
respectively.
The possible impact of IRB review could only be veriﬁed
for the variable items and not the always-fulﬁlled or always-
missing items. Items like trial site details, beneﬁts to subjects,
exclusion criteria, subjects’ follow up after adverse events,
and ethical considerations were signiﬁcantly better for IRCTPs
compared to non-IRCTPs. Items like stopping rules, with-
drawal criteria for individual subjects and monitoring of treat-
ment compliance were signiﬁcantly better in the non-IRCTPs.
The rest of items in this third pattern were not different in the
IRCTPs compared to the non-IRCTPs (Table 4). Regarding
individual items’ AS, the general information score, treatment
score, ethics score were signiﬁcantly higher for IRCTPs than
non-IRCTPs. Data handling was signiﬁcantly better in the
non-IRCTPs. The rest of items were not statistically different
in the two groups (Table 5). When items were categorized, eth-
ical, administrative and protocol AS were signiﬁcantly better
for the IRCTPs than non-IRCTPs. Meanwhile, the scientiﬁc
score was similar in both groups.Discussion
Our study, as we believe, is the ﬁrst to address the issue of com-
pliance of oncology CTPs to the ICH guidelines for protocol
structure in academia outside ICH boundaries. At NCI-Egypt,
academic CTPs are developed by post-graduate students under
supervision of NCI teaching staff or by the teaching staff
themselves in the concerned departments. As expected, the sci-
entiﬁc part of the protocol was well developed in the majority
of the protocols. This is conﬁrmed in our trial where the back-
ground information (literature search), objectives and purpose,
inclusion criteria and description of study treatments are al-
ways fulﬁlled in all of the reviewed protocols. However as most
of the trials were from the clinical departments and there were
no phase I trials, preclinical data were missing in most of the
protocols. This should not be the case and preclinical data
are very important and needs inclusion in every protocol at
least in a concise manner.
Researcher enthusiasm and, may be, bias in favor of the
experimental intervention is reﬂected in lack of consideration
of early study termination through interim analysis, failure
to mention subject withdrawal criteria in 88%, mentioning po-
tential beneﬁts in 77% and risks in only 38%, inclusion of
safety assessment in 75%, and anticipating adverse events
and stating the tools to record them in only 33% of protocols.
Table 2 ICH Items that are always fulﬁlled in all protocols.
1. General information
1.1. Protocol title and date
1.3. Name and title of the persons authorized to sign the protocol
1.4. Name and title of the sponsor’s medical expert for the trials
1.5. Name and title of the investigator who is responsible for conducting the trial (i.e. the candidate)
1.7. Details of departments and/or institutions involved in the trial
2. Background information
2.1. Name and description of the investigational product(s)
2.2. Summary of ﬁndings from clinical trials that are relevant to the trial
2.6. Description of the population to be studied
2.7. References to literature and data that are relevant to and provide background for the trial
3. Trial objectives and purpose
3.1. Purpose
3.2. Objectives
4. Trial design
4.4. Description of the trial treatments
4.8. Maintenance of randomization codes and procedures for breaking codes
5. Selection and withdrawal of subjects
5.1. Subject inclusion criteria
6. Treatment of subjects
6.1. Details of the treatments to be administered
Table 3 ICH items that are always missing in all protocols.
1. General information
1.2. Name and address of the sponsor and monitor (if other than the sponsor)
1.4. Address, and telephone numbers of the sponsor’s medical expert for the trial
4. Trial design
4.6. Description of the ‘‘stopping rules’’ or ‘‘discontinuation criteria’’ for parts of the trial or the entire trial
4.7. Accountability procedures for the investigational product(s), including the placebo(s) and comparator(s), if any
4.8. Maintenance of trial treatment randomization codes and procedures for breaking codes
4.9. The identiﬁcation of any data to be recorded directly on the CRFs, and considered to be source data
9. Statistics
9.1. Timing of any planned interim analysis
9.4. Criteria for the termination of the trial
9.5. Procedure for accounting for missing, unused, and spurious data
9.6. Procedures for reporting any deviation(s) from the original statistical plan
10. Direct access to source data/documents
11. Quality assurance and control
13. Record keeping
14. Financing and insurance
15. Publication policy
74 A.A. ZeeneldinWhile this enthusiasm is good, it should be trimmed and
should not obscure the potential harms and the researcher
should be prepared to deal with harms if they occur.
Involvement of the statistician very early in the study design
is not a common practice at the NCI-Egypt. This is reﬂected in
the reviewed protocols through unspeciﬁed design and statisti-
cal methods in 20% and 47% respectively, lack of justiﬁcation
for the chosen sample size in 56%, failure to mention the sig-
niﬁcance level and the analysis set in 53% and 92% respec-
tively, non-adoption of interim analysis and non-speciﬁcation
of statistical criteria for trial termination, and lack of consider-
ation of how missing and spurious data and protocol devia-
tions will be dealt with. However, this practice should be
discouraged and the statistician should be an integral member
of any research team from the early phase of trial design.Academic trials at NCI-Egypt are largely dependent on the
researcher with little support from research nurses, data man-
agers, trial coordinators, monitors or trial pharmacists. More-
over, structured training in research methods and data
collection is lacking. This is reﬂected in the reviewed protocols
by the lack of consideration of data handling, access to source
data, record keeping and the rare inclusion of CRFs as supple-
ments to the protocols. Also quality assurance and control
were not considered. This situation clearly points to how over-
burdened are the researchers at NCI-Egypt and the need for
their support to better manage the trials for better quality
and more productivity. Setting a research center that provides
this support and training to different members of the research
team in all trial related activities as well as monitoring of aca-
demic trial conduct is eagerly needed.
Table 4 ICH items variably encountered in the protocols.
Items All IRCTPs Non-IRCTPs p Value
N (%) N (%) N (%)
Total numbers 60 (100) 30 (100) 30 (100) –
1. General information
1.5. Details of the trial sites 38 (63) 30 (100) 8 (27) <0.001
1.7. Details of laboratories involved in the trial (n= 32) 1/32 (3) 0 (0) 1 (3) –
2. Background Information
2.2. Summary of ﬁndings from nonclinical studies 7 (12) 2 (7) 5 (17) 0.42
2.3. Summary of the known and potential risks 23 (38) 11 (37) 12 (40) 1.00
2.3. Summary of the expected beneﬁts 46 (77) 27 (90) 19 (63) 0.03
2.4. Description of and justiﬁcation for the
route, dose, dose regimen, and treatment periods (n= 36)
35/36 (97) 12/12 (100) 23/24 (96)
2.5. A statement that the trial will be conducted in compliance
with the protocol, GCP and the applicable regulatory requirements
2 (3) 2 (6) 0 (0) –
4. Trial design
4.1. A speciﬁc statement of primary endpoints 54 (90) 28 (93) 26 (87) 0.67
4.1. A speciﬁc statement of secondary endpoints 50 (83) 27 (90) 23 (77) 0.29
4.2. A description of trial type/design 42 (70) 20 (67) 22 (73) 0.78
4.2. Schematic diagrams of design, procedures and stages 7 (12) 1 (3) 6 (20) 0.10
4.3. Description of randomization 19 (32) 8 (27) 11 (37) 0.58
4.3. Description of blinding 4 (7) 3 (10) 1 (3) 0.61
4.4. Description of the dosage form of IP (n= 39) 39/41 (95) 13/14 (93) 26/27 (96)
4.4. Description of packaging and labeling of IP 1/7 (14) 1/2 (50) 0/5 (0) 0.14
4.5. Expected duration of subject participation 41 (68) 17 (57) 24 (80) 0.52
4.5. Description of the sequence of all trial periods 50 (83) 23 (77) 27 (90) 0.29
4.5. Description of the duration of trial periods 49 (82) 25 (83) 24 (80) 0.73
4.6. Description of the ‘‘stopping rules’’ or ‘‘discontinuation
criteria’’ for individual subjects
11 (18) 0 (0) 11 (37) <0.001
5. Selection and withdrawal of subjects
5.2. Subject exclusion criteria 48 (80) 28 (93) 20 (67) 0.02
5.3. Subject withdrawal criteria 7 (12) 0 (0) 7 (23) 0.01
6. Treatment of subjects
6.2. Permitted medications/treatments 8 (13) 5 (17) 3 (10) 0.70
6.2. Forbidden medications/treatments 5 (8) 5 (17) 0 (0) 0.05
6.3. Procedures for monitoring compliance (n= 32) 4/32 (13) 0/5 (0) 4/27 (15) <0.001
7. Assessment of eﬃcacy
7.1. Speciﬁcation of the eﬃcacy parameters 58 (97) 29 (97) 29 (97) 1
7.2. Methods and timing for assessing, recording and analyzing eﬃcacy parameters 55 (92) 29 (97) 26 (87) 0.35
8. Assessment of safety
8.1. Speciﬁcation of safety parameters 45 (75) 23 (77) 22 (73) 0.76
8.2. The methods and timing for assessing, recording and analyzing safety parameters 45 (75) 23 (77) 22 (73) 0.76
8.3. Procedures for eliciting reports of and for recording and reporting AEs and illnesses 20 (33) 13 (43) 7 (23) 0.17
8.4. The type and duration of the follow-up of subjects after adverse events 24 (40) 17 (57) 7 (23) 0.01
9. Statistics
9.1. Description of statistical methods 32 (53) 17 (57) 15 (50) 0.60
9.2. The number of planned subjects to enroll 54 (90) 28 (93) 26 (87) 0.38
9.2. Reason for choice of sample size (n= 54) 24/54 (44) 13 (43) 11 (37) 0.59
9.3. The level of signiﬁcance to be used 28 (47) 13 (43) 15 (50) 0.60
9.7. The selection of analyzable subjects 5 (8) 2 (7) 3 (10) 1.00
12. Ethics 31 (52) 21 (70) 10 (33) 0.004
13. Data handling 4 (7) 0 (0) 4 (13) 0.11
16. Supplements 23 (38) 19 (63) 4 (13) <0.001
16.1. Consent 19 (32) 19 (63) 0 (0) <0.001
16.2. Case report forms 4 (7) 0 (0) 4 (13) 0.04
IRCTPs, Institutional Review Board-reviewed clinical trial protocols; GCP, good clinical practice; IP, investigational product; CRF, case report
form; AE, adverse events.
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the IRCTPs than the non-IRCTPs. However, ethical consider-
ations that pertain to clinical trials are many and are not lim-
ited to the informed consent. They include, among many other
issues, trial speciﬁc issues like randomization, placebo use, vul-nerability, and selection criteria. Apart from the consent, none
of these issues were considered from ethical view point when-
ever relevant. None of the 8 pediatric trials mentioned the issue
of assent. This highlights the urgent need to train researchers
in research ethics. While it is mandatory for any IRB to review
Table 5 Mean ± SD of adherence scores (AS) of individual protocol items, grouped items and the entire protocols.
No Item All IRCTPs Non-IRCTPs p Value
I. Individual items
1 General information 70 ± 8 76 ± 4 64 ± 6 <0.001
2 Background information 77 ± 10 75 ± 8 79 ± 11 0.14
3 Trial objectives and purpose 100 ± 0 100 ± 0 100 ± 0 *
4 Trial design 49 ± 11 47 ± 12 52 ± 10 0.08
5 Selection and withdrawal of subjects 31 ± 16 28 ± 4 34 ± 21 0.11
6 Treatment of subjects 36 ± 16 41 ± 18 32 ± 12 0.03
7 Assessment of eﬃcacy 94 ± 21 97 ± 18 92 ± 23 0.36
8 Assessment of safety 56 ± 38 63 ± 39 48 ± 35 0.13
9 Statistics 30 ± 18 31 ± 18 29 ± 18 0.80
10 Direct access to source data/documents 13 ± 0 13 ± 0 13 ± 0 1.00
11 Quality control and quality assurance 13 ± 0 13 ± 0 13 ± 0 1.00
12 Ethics 52 ± 50 70 ± 47 33 ± 48 0.004
13 Data handling and record keeping 3 ± 13 0 ± 0 7 ± 17 0.04
14 Financing and insurance 0 ± 0 0 ± 0 0 ± 0 *
15 Publication policy 0 ± 0 0 ± 0 0 ± 0 *
16 Supplements 19 ± 25 32 ± 25 7 ± 17 0.003
II. Grouped items
A. Administrative score 19 ± 5 22 ± 4 16 ± 3 <0.001
B. Ethics score 52 ± 50 70 ± 47 33 ± 48 0.004
C. Scientiﬁc score 54 ± 8 54 ± 7 54 ± 9 0.87
III. Protocol (total) adherence score 41 ± 6 43 ± 6 38 ± 6 0.003
IRCTPs, Institutional Review Board-reviewed clinical trial protocols; SD, standard deviation; *p value was not calculated as both groups are
exactly the same.
76 A.A. Zeeneldinthe consent, the consent was mentioned in the IRB-reviewed
protocol in 70% of cases. This may mean that the IRB mem-
bers do not insist that written consent is mentioned as an inclu-
sion criterion.
General information regarding contact information (ad-
dress and telephone) of trial personnel, sites and laboratories
were lacking. We think that this reﬂects the concept that these
trials are conducted exclusively in NCI-Egypt. However, this is
not a plausible reason for missing this information at least to
ease communication when needed.
Financing and insurance issues were lacking in all proto-
cols. Despite all trials are sponsored by NCI-Egypt, no bud-
gets were included. However, researchers were not
compensated for the signiﬁcant time and efforts spent during
trials. Moreover, they may spend out-of-pocket money to cov-
er issues like computer edits, data entry and analysis. This atti-
tude should be changed and researchers should be trained and
offered support to develop a budget of every trial. This budget
should include all aspects to avoid researcher’s out-of-pocket
payments. Trial insurance is lacking at NCI-Egypt. While no
issues of subject compensation were raised so far, this could
happen at any time and the higher NCI-Egypt administration
should be careful about this issue as it may be disastrous.
Record keeping was not discussed in any of the protocols.
Source documents are managed according to the routine
NCI-Egypt practices. However, research documents lack clear
guidelines regarding how and for how long they should be
kept. Publication policy was not mentioned in any of the pro-
tocols and there are no guidelines regarding this issue at NCI-
Egypt and these need consideration to avoid conﬂicts that may
arise when publications are done after trial completion.
The implementation of the mandatory IRB review of CTPs
at NCI-Egypt in 2008 was associated with signiﬁcantly higher
scores for ethics, treatment details and general protocol infor-mation. When grouped, the beneﬁcial effects were noticed in
the ethical and administrative group of items. This can be a di-
rect effect of the review process with these parameters forming
the main focus of review. The scientiﬁc score was similar in
both IRCTPs and non-IRCTPs. This reﬂects the reasonable
scientiﬁc content of all protocols. Moreover, science is not
the main focus of an IRB review as this was left for the con-
cerned clinical department.
Items like background information, trial objectives, assess-
ment of efﬁcacy and safety, and trial design were equally good
for IRCTPs and non-IRCTPs with no signiﬁcant differences.
However, items like subject selection and withdrawal, statis-
tics, access to source data, quality assurance and control,
ﬁnancing and insurance and publication policy were equally
bad for IRCTPs and non-IRCTPs with no signiﬁcant differ-
ences. These need to be included in researcher training and
awareness as well as in the institution guidelines and policies.
Total protocol adherence score was signiﬁcantly better for
IRCTPs and non-IRCTPs (43% vs. 38%, respectively, p
0.003) mainly due to improvement of the ethical parts (from
70% vs. 33%, p 0.004) and administrative parts (from 22%
vs. 16%, p < 0.001). However, this is far beyond a desirable
level.
Our results are similar to that of single institution study
from Spain that reviewed the quality of protocols submitted
to a newly developed IEC where the most frequent deﬁciencies
were related to statistical analysis, patient selection criteria,
choice of sample size, concomitant medication, monitoring
of adverse events, compliance of subjects and experimental de-
sign. Lack of insurance for the people and institutions in-
volved, and inadequacies in the investigators’ brochure and
case report forms were also encountered. However, the differ-
ence in percentage of deﬁciency reﬂects time and settings var-
iance [7]. Moreover, their assessments were based on a
Adherence of academic oncology trial protocols to ICH guidelines 77checklist that relied on published criteria and personal experi-
ence. They came to the conclusion that multidisciplinary teams
should be included in the design of protocols.
Our study has some limitations. It is retrospective and in
the setting of one academic institution in the ﬁeld of oncology.
However, we believe that it was very difﬁcult if we were to con-
duct this study in a prospective fashion as it would take a very
long time with no or little difference in the outcome. More-
over, retrospective studies accurately reﬂect the community
practice and needs fewer resources than prospective ones [8].
The second limitation of our study is that it involved CTPs
from academic trials excluding pharmaceutically sponsored
ones. This limits the generalizability of our ﬁndings to non-
academic trials. However, we do believe that pharma has cut
a long way in complying with regulations and guidelines. They
have the resources and expertise to ensure compliance directly
through their own staff or indirectly through outsourcing.
More importantly is the motivation; if they are not to comply,
their application for an approval of a new drug or device may
be rejected. This is not the case in academia where motivation,
expertise and the resources are less. So, most of the time, aca-
demia needs support to comply with rules and regulations. The
third limitation is that our study was limited to the ﬁeld of
oncology and included only one center, NCI-Egypt. However,
cancer is the most researched disease; a review of research pro-
tocols submitted to local IECs in Italy revealed that cancer tri-
als represented 23% of all trials with breast cancer being the
most researched topic [9]. Limited accessibility to clinical re-
search data in Egypt is prevalent. Unlike the US National
Institute of Health trial registry like that of clinicaltrials.gov
[10], trials in Egypt are not registered in a publicly accessible
way and the protocols are mostly considered conﬁdential.
Thus, it would be difﬁcult to access data from outside the insti-
tute in which the researcher is working where he can get the
permission to review the protocols through personal communi-
cation with the higher institutional administration and to ex-
plain the research in detail.
Selection and assessment of CTPs for adherence to ICH
protocol guidelines were carried out by a single researcher with
the potential for bias. Ideally, such bias would be overcome
when two independent reviewers assess CTP quality. However,
to limit the selection bias, all consequent CTPs that immedi-
ately preceded and followed the mandate of IRB review were
included.
This study adopted the before-and-after design [11]. De-
spite the ethical and administrative sections of CTPs had im-
proved during the period following the mandate of IRB
review compared to the preceding period, we cannot infer a
causal relationship as the study was observational.
Recommendations and outcomes of this study
The ICH E6(R1) guidelines for CTPs can serve as a good
explanatory document that can help academic researchers in
writing their study protocols. Based on this document together
with some modiﬁcations to suit the NCI-Egypt peculiarities,
we have developed a CTP template and made it available for
comments of NCI researchers then it will be publicly available
through the NCI-Egypt website and may be adopted as the
mandate template. The CRF we developed may be used as a
checklist to be completed by the researchers to assure that theirprotocol was thought of from all aspects. It can also be used by
research committees to assess protocol quality.
The difﬁculties we faced with accessing CTPs ignited the
proposal for registering trials in a speciﬁc electronic database
that can be publicly available through NCI-Egypt website.
Old CTPs will be scanned and uploaded as well. When com-
pleted, this NCI-Egypt trial registry will include almost all aca-
demic CTPs performed at this institution.
Given the utmost importance of the protocol in any study,
we propose that formal training on protocol writing skills be
conducted regularly at NCI-Egypt with input from epidemiol-
ogists/biostatisticians, ethicists, data managers as well as the
relevant departments. This training will provide both the the-
oretical background for the topic and also will guide the
researchers while preparing their own protocols.
Funding
This work is investigator initiated with no external funding or
support.
Disclosure statement
The author denies any actual or potential conﬂict of interest;
ﬁnancial or otherwise.Acknowledgements
This work was done as a dissertation to fulﬁll the requirements
for achievement of a Master Degree in Clinical Research
Administration (CRA) at Liverpool University, UK. This is
an online educational program with partnership between Uni-
versity of Liverpool Online Higher Education and Laureate
Online Education. The thesis was performed under supervision
of Dr. Stephen Stoller, director of CRA online studies with
great advice from Dr. Jill Wiseberg; the General Dissertation
advisor, and Dr. Rebecca Ballard; the initial Dissertation
Advisor.
References
[1] World Medical Association. WMA declaration of Helsinki –
ethical principles for medical research involving human subjects;
2008. Available from: http://www.wma.net/en/30publications/
10policies/b3/index.html (accessed 20/8/2010).
[2] Pocock SJ. Clinical trials: a practical approach. NJ: Wiley
Press; 1983, 14–26, 28–41.
[3] Internationl Conference on Harmonization (ICH E6).
Guidelines for good clinical practice E6(R1): clinical trial
protocol and protocol amendment(s); 1996. Available from:
http://www.ich.org/LOB/media/MEDIA482.pdf (accessed 20/5/
2010).
[4] Lepay A. FDA GCP enforcement strategies and options, APEC
GCP inspection workshop; 2008. Available from: http://
www.ich.org/ﬁleadmin/Public_Web_Site/Training/GCG_-_
Endorsed_Training_Events/APEC_LSIF_FDA_prelim_ work
shop_Bangkok__Thailand_May_08/Day_4/FDA_Enforcement
_Strategies_Options_Lepay_FDA.pdf (accessed 20 May 2011).
[5] National Cancer Institute, Cairo University, Egypt. National
Cancer Institute, Egypt; 2010. Available from: http://
www.nci.cu.edu.eg/ (accessed 30/10/2010).
78 A.A. Zeeneldin[6] Chow S, Liu J. Preparation and implementation of a clinical
protocol. In: Chow S, Liu J, editors. Design and analysis of
clinical trials. New Jersey: Wiley-IEEE Press; 2004. p. 602–12.
[7] Garcı´a-Cases C, Duque A, Borja J, Izquierdo I, et al.
Evaluation of the methodological quality of clinical trial
protocols. A preliminary experience in Spain. Eur J Clin
Pharmacol 1993;44(4):401–2.
[8] Hess D. Retrospective studies and chart reviews. Respir Care
2004;49(10):1171–4.
[9] Venturini F, Alberti C, Alberti MP, Scroccaro G. Clinical trials
in Italy: focus on the protocols submitted to ethics committees. J
Clin Pharm Ther 2001;26(2):103–10.[10] US National Institute of Health (n.d.) Clinicaltrials.gov.
Available from: http://clinicaltrials.gov/ct2/search (accessed 30
May 2011).
[11] Institute for Work & Health, National Institute for
Occupational Safety and Health. Guide to evaluating the
effectiveness of strategies for preventing work injuries: How to
show whether a safety intervention really works; 2001. Available
from: http://www.iwh.on.ca/system/ﬁles/documents/evaluation_
guide_2001b.pdf (accessed 6 December 2012).
